GREAT SCIENCE. GREAT MEDICINE.
CREATING BREAKTHROUGH TREATMENTS.
HGS is working to create and develop novel therapies that can extend and improve the quality of life. That is our passion.
Three Products in Late-Stage Development
We now have three promising products in late-stage development, moving toward commercialization. We have reported the positive results of two Phase 3 trials of Albuferon®, and we plan to file global marketing applications in fall 2009. Two Phase 3 trials are ongoing for BENLYSTA™ (formerly LymphoStat-B®) in patients with lupus, with results expected in July and November 2009. We are developing both of these products in collaboration with world leaders in the pharmaceutical industry. Also in late-stage development is ABthrax™, which offers a new way to address the threat of inhalation anthrax and is being developed under a contract with the U.S. Government.
High-Potential Pipeline
Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by our TRAIL receptor antibodies for cancer. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK has initiated Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease, and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
We are committed to improving the lives of patients – and to achieving commercial success and sustainable growth well into the future.